{
    "clinical_study": {
        "@rank": "77060", 
        "arm_group": {
            "arm_group_label": "Radiation Therapy", 
            "arm_group_type": "Experimental", 
            "description": "Radiation Therapy"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to determine the maximum tolerated dose of hypo-fractionated\n      radiation therapy and the toxicity of the treatment program.\n\n      Eligible patients with stage T1-2c prostate cancer who sign consent will be enrolled to this\n      phase I dose escalation trial and be treated with hypo-fractionated radiation therapy (HRT).\n      Dose escalation will be as follows:\n\n      There will be 3 cohorts consisting of 3 patients each."
        }, 
        "brief_title": "Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer", 
        "completion_date": {
            "#text": "July 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Dose escalation will be as follows:\n\n      There will be 3 cohorts consisting of 3 patients each. All patients will receive 18\n      fractions of HRT over the course of 6 weeks (3 fractions per week). Dose level I will be\n      54Gy (3 Gy per fraction), dose level II will be 55.8 Gy (3.1Gy per fraction), dose level III\n      will be 57.6 Gy (3.2 Gy per fraction). After accrual of dose level I, all patients will be\n      observed for a minimum of two weeks after completion of radiation treatments, for assessment\n      of toxicity, before the dose can be escalated for the next cohort. After dose level II,\n      patients will be observed for 6 months before enrolling patients on dose level III.\n\n      All patients will be seen weekly by their radiation oncologist during radiation therapy. Any\n      observations regarding radiation reactions will be recorded."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History/physical examination with digital rectal examination of the prostate within 8\n             weeks prior to registration\n\n          -  Clinical stage T1-2c (AJCC 6th edition)\n\n          -  Gleason <6 and PSA <10 ng/mL\n\n          -  Gleason =7 and/or PSA 10-20 ng/mL provided <34% of core biopsies are positive for\n             carcinoma\n\n          -  PSA < 20 ng/mL within 180 days prior to registration. PSA should not be obtained for\n             at least 10 days after prostate biopsy.\n\n          -  Zubrod performance status 0-1\n\n          -  Age \u2265 18\n\n          -  Patient must sign study specific informed consent prior to randomization.\n\n        Exclusion Criteria:\n\n          -  Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or\n             lymphomatous/hematogenous malignancy unless continually disease free for a minimum of\n             5 years. (For example, carcinoma in situ of the bladder or oral cavity is\n             permissible)\n\n          -  Evidence of distant metastases\n\n          -  Regional lymph node involvement\n\n          -  Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer\n\n          -  Prior androgen deprivation therapy (ADT)\n\n          -  Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy\n\n          -  Previous or concurrent cytotoxic chemotherapy for prostate cancer"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677845", 
            "org_study_id": "S12-00867"
        }, 
        "intervention": {
            "arm_group_label": "Radiation Therapy", 
            "description": "Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;\nDose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;\nDose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions.", 
            "intervention_name": "Radiation", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Localized Prostate Cancer", 
            "Radiation"
        ], 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "contact": {
                "last_name": "Nicholas J Sanfilippo, M.D.", 
                "phone": "212-731-5041"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "NYU Langone Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Nicholas J. Sanfilippo, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Herbert Lepor, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Samit Taneja, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "William Huang, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Silvia C Formenti, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Barry Rosenstein, Ph.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of Hypo-Fractionated Radiation Therapy (HRT) for Localized Prostate Cancer", 
        "overall_contact": {
            "email": "Ravindran.Kathirithamby@nyumc.org", 
            "last_name": "Ravindran Kathirithamby", 
            "phone": "212-731-5335"
        }, 
        "overall_official": {
            "affiliation": "NYU Langone Medical Center, Departement of Radiation Oncology", 
            "last_name": "Nicholas J Sanfilippo, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "After accrual of dose level I, all patients will be observed for a minimum of two weeks after completion of radiation treatments, for assessment of toxicity, before the dose can be escalated for the next cohort. After dose level II, patients will be observed for 6 months before enrolling patients on dose level III.", 
            "measure": "the maximum tolerated dose of HRT", 
            "safety_issue": "Yes", 
            "time_frame": "30 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677845"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "New York University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "New York University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}